Wolfe Research analyst Scott Group upgrades Matson (NYSE:MATX) from Underperform to Peer Perform.
SVB Leerink Downgrades Horizon Therapeutics to Market Perform, Raises Price Target to $116.5
SVB Leerink analyst David Risinger downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform and raises the price target from $88 to $116.5.